Free lookups: 0/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
0 of 3 free lookups remaining Upgrade
New search Medicine profile Choline Salicylate 8.7 %W/V+Lignocaine 2 %W/V

Clinical medicine profile

Choline Salicylate 8.7 %W/V+Lignocaine 2 %W/V

Therapeutic agent (verify pharmacological class)

POM
Evidence state General guidance Reviewed 14 Aug 2026
Route
See product SmPC
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • [From component Lignocaine + Adrenaline injection] Children below 12yrs.
  • Allergy to any component of the formulation.
  • Use on fingers, toes, the tip of nose, ears, and penis since the product contains adrenaline.

Precautions

  • Obtain allergy and medication history.
  • Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs.
  • Use the lowest effective dose for the shortest appropriate duration.
  • Monitor for expected class adverse effects.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.

Paediatric

Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

03 Clinical use

Use, effects & interactions

Indications

  • Analgesic, antiseptic, anaesthetic
  • gel for mouth sore Clinical selection for Choline Salicylate 8.7 %W/V+Lignocaine 2 %W/V should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Therapeutic agent (verify pharmacological class).
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • [From component Lignocaine + Adrenaline injection] Acute toxic reactions in case of accidental intravascular injection.
  • Drowsiness
  • dizziness
  • disorientation
  • confusion
  • lightheadedness
  • psychosis
  • apprehension
  • tinnitus
  • visual disturbances including amblyopia or diplopia
  • vomiting
  • paraesthesia
  • sensations of heat, cold, or numbness
  • difficulty swallowing
  • Fixed-dose/multi-ingredient product.
  • Clinical details partially inherited from component monographs: Lignocaine + Adrenaline injection.
  • Confirm combination SmPC for exact dosing.
04 Pharmacology

Mechanism & disposition

Combination product.

Combination product.Component mechanism (Lignocaine + Adrenali…Adrenaline, a vasoconstrictor, prevents th…
Read complete mechanism

Combination product. Component mechanism (Lignocaine + Adrenaline injection): Lignocaine acts by stabilizing the membranes of the nerve cells by decreasing their permeability to sodium ions. Adrenaline, a vasoconstrictor, prevents the extensive spread of lignocaine.

Onset

Product-specific

Duration

Product-specific

Route

See product SmPC

Elimination

are product-specific. Consider food effects, protein binding, hepatic CYP/UGT

Half-life

when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

FromKES 180
MedianKES 180
Listings1
BrandManufacturerPackObserved price
DENTOGEL DAIMA BIASHARA / Wholesale Import GEL 10G KES 180.24Daima Chemist price-list reference ↗ Source date not recorded · verify current price
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Component monographs (multi-source pipeline); Professional class pharmacology (Therapeutic agent (verify pharmacological class))
Last reviewed14 Aug 2026
EvidenceGeneral guidance

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.